Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market

[ad_1]

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion. 

[ad_2]

Source link